Attention www.globalkeysolutions.net is now www.keypedia.com, read the full press release here.
KeyPedia LogoKeyPedia Icon
  1. Home
  2. /
  3. Records
  4. /
  5. Eir
  6. /
  7. Bora Pharmaceuticals Inc.
EIR
•Bora Pharmaceuticals Inc.•June 21, 2018

Bora Pharmaceuticals Inc. – FDA EIR, Jun 21, 2018

Record Details

Upsher Smith Laboratories, Inc. underwent a routine FDA inspection from June 20-21, 2018, at its Maple Grove, MN facility. The inspection's primary focus was Postmarketing Adverse Event Drug Experience (PADE) reporting for human drug and dietary supplement products, conducted under Compliance Program 7353.001. During this two-day inspection, a comprehensive review of the company's adverse event processes was performed. This included examination of individual case safety reports, periodic reports, written procedures, safety data exchange agreements, and the firm's system for contracting out adverse event handling to a third-party vendor. The FDA noted that all previous observations from a 2014 PADE inspection, which had resulted in a "Voluntary Action Indicated" classification due to issues like undocumented PADE training and procedural gaps, were observed to have been corrected. Crucially, no Form FDA-483 (Inspectional Observations) was issued, nor were any verbal issues discussed with management at the conclusion of the June 2018 inspection. The FDA found no failures in adhering to written procedures or instances of late expedited reporting. The firm demonstrated a compliant status, having implemented a robust pharmacovigilance system, including a thoroughly assessed third-party vendor for adverse event processing. Consequently, no new regulatory actions were required from Upsher Smith Laboratories, Inc.

Company
Bora Pharmaceuticals Inc.
Inspection date
June 21, 2018
Product type
drugs
Office
Minneapolis District Office
Person
  • Kellie L. Thommes (Consumer Safety Officer)
View Company Profile

ID · 0a3a82b6-ab2f-4e82-b028-821e1adc5ee3

Violation Codes1
21 CFR 11

Full citation text and observation details available on the Dashboard.

Other documents for Bora Pharmaceuticals Inc.
  • 483 - 2024-07-11July 11, 2024
  • 483 - 2022-08-30August 30, 2022
  • 483 - 2018-12-19December 19, 2018

Your cart

Your cart is empty.

Browse public document pages and click Buy this document. We'll ask for your email at checkout, no account needed up front.

Browse documents

Discuss this record with AI

KeyPedia

ChatGPT

Claude

Perplexity

Grok

Copilot

Document or profile

One record shows the event. A profile shows the pattern.

Buy this document for the source file and details behind this single event.

Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.

Explore Bora Pharmaceuticals Inc.
KeyPedia
Regulatory Data Transformed
Stay in the loop

KRA score changes, company updates and news. About monthly, unsubscribe anytime.

Contact
New York Office:
370 Jay Street 7th Floor
Brooklyn, NY 11201
Scranton Office:
Scranton Enterprise Center, Suite 217
201 Lackawanna Avenue
Scranton, PA, 18503
🇺🇸+1 917-789-5099
🇪🇺+48 532-447-507
info@keypedia.com
Quick Links
HomePlatform OverviewMedia
KeyPedia™ Lite
Browse HubDatabase DirectoryRecordsCompaniesOfficesPeopleCareersAbout UsFounding TeamMeet Our ExpertsPartners
Legal & Ethics
Privacy PolicyTerms of ServiceOur Values & MissionCode of Ethics & AI Policy
©2026 KeyPedia™ | Global Key Solutions Corp. All rights reserved.